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ABSTRACT
Introduction Community- acquired pneumonia (CAP) 
causes around 10 hospitalisations per 1000 child- years, 
each associated with an average 13 non- routine days 
experienced and more than 4 parent workdays lost. 
In adults, steroid treatment shortens time to clinical 
stabilisation without an increase in complications in 
patients with CAP. However, despite promising data from 
observational studies, there is a lack of high- quality 
evidence for the use of steroids.
Methods and analysis The KIDS- STEP trial is a 
multicentre, randomised, double- blind, placebo- 
controlled superiority trial of betamethasone treatment 
on outcome of hospitalised children with CAP. Children 
are enrolled in paediatric emergency departments of 
hospitals across Switzerland and randomised to adjunct 
oral betamethasone for 2 days or matching placebo in 
addition to standard of care treatment. The co- primary 
outcomes are the proportion of children clinically stable 
48 hours after randomisation and the proportion of 
children with CAP- related readmission within 28 days 
after randomisation. Secondary outcomes include length 
of hospital stay, time away from routine childcare and 
healthcare utilisation and total antibiotic prescriptions 
within 28 days from randomisation.
Each of the co- primary outcomes will be analysed 
separately. We will test clinical stability rates using a 
proportion test; to test non- inferiority in readmission rates, 
we will construct 1−α % CI of the estimated difference 
and test if it contains the pre- defined margin of 7%. 
Success is conditional on both tests. A simulation- based 
sample size estimation determined that recruiting 700 
patients will ensure a power of 80% for the study.
Ethics and dissemination The trial protocol and 
materials were approved by ethics committees in 
Switzerland (lead: Ethikkommission Nordwest und 
Zentralschweiz) and the regulatory authority Swissmedic. 
Participants and caregivers provide informed consent prior 
to study procedures commencing. The trial results will 
be published in peer- reviewed journals and at national 
and international conferences. Key messages will also 
be disseminated via press and social media where 
appropriate.
Trial registration number NCT03474991 and 
SNCTP000002864.
INTRODUCTION
The incidence of community- acquired pneu-
monia (CAP) in young children remains 
high (30–40/1000 child- years) even in high- 
income settings with routine pneumococcal 
vaccination, and is associated with a high rate 
of hospitalisation (around 10/1000 child- 
years).1 In low- income and middle- income 
settings, pneumonia is the leading infectious 
cause of death in children less than 5 years of 
Strengths and limitations of this study
 ► This well- powered multi- centre trial will provide 
high- quality evidence on efficacy of adjunct steroid 
treatment for uncomplicated community- acquired 
pneumonia (CAP) in children.
 ► Because clinically defined CAP contains mixed se-
verities and aetiologies, overall results may miss 
divergent effects in specific subpopulations.
 ► Despite exclusion of children with alternative diag-
noses, a clinical diagnosis may have limited speci-
ficity for CAP.
 ► The pragmatic approach to eligibility employed by 
the KIDS- STEP trial is aligned with clinical practice 
and so will facilitate rapid knowledge translation.
 ► The generalisability of the KIDS- STEP trial findings 
will be maximised by the wide age range and the 
diverse aetiology of CAP in the enrolled population.
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age.2 In high- income settings, working mothers of chil-
dren hospitalised with CAP have been reported to lose 
on average 4.2 workdays compared with 1.7 workdays for 
children with CAP managed in primary care.3 In addition 
to this economic burden, there is a substantial impact on 
quality of life for the affected child and the family.3 Chil-
dren who are admitted with CAP experience on average 
13 non- routine days as judged by their parents or care-
givers when assessed with a standardised quality of life 
questionnaire. Periods of decreased appetite (8.5 days), 
disordered sleep (4.5 days) and the absence from routine 
out- of- home childcare (7.5 days) were slightly shorter.3 
Any intervention that ensures rapid clinical stabilisation 
allowing for early hospital discharge without negative 
impacts on the overall recovery in children hospitalised 
with CAP would, therefore, carry substantial socioeco-
nomic benefits.
Adjunct systemic corticosteroids shorten the time until 
clinical stability is reached in adult patients.4 Comparable 
data for paediatric patients applicable to an unselected 
group of children with moderate–severe CAP are not 
available. The most recent Cochrane meta- analysis found 
evidence for a benefit from steroid treatment, but for 
children this was based on a small number of very hetero-
geneous and mostly unblinded trials aiming to investigate 
the efficacy of steroids in pneumonia with detection of 
specific pathogens, for example, Mycoplasma pneumoniae 
or respiratory syncytial virus (RSV).5
Infection- related unwanted effects of adjunct steroids 
are potentially relevant in the context of childhood CAP. 
A higher proportion of children hospitalised with CAP 
reaching early clinical stability would only be desirable 
if this would not to be offset by a higher rate of clini-
cally relevant CAP recurrence. A rebound phenomenon 
after corticosteroid discontinuation has been postulated 
to explain a higher rate of infection recurrence (19% 
compared with 9% in placebo group) among adults.6 
Data from a recent individual patient’s data meta- analysis, 
however, indicate that an increased risk of CAP recur-
rence may be observed,7 potentially associated with a 
longer duration of adjunct steroids in adults with CAP. To 
the best of our knowledge, the question about the effect 
of adjunct steroid treatment in childhood CAP in relation 
to a postulated rebound phenomenon measured clini-
cally as CAP recurrence has not been formally addressed 
in a trial. CAP- specific readmission rates for children are 
low at around 5%.8 9 In bronchiolitis, another acute lower 
respiratory tract infection for which oral corticosteroid 
treatment has been investigated, an increased risk of 
hospital revisits associated with steroid treatment could 
not be identified in a Cochrane meta- analysis.10
WHO has identified studies on the effect of steroids 
in the novel COVID-19 as a priority during the current 
pandemic.11 While there is no evidence suggesting a 
harmful effect of steroids on paediatric patients, studies 
in adults have identified a longer duration of viral shed-
ding after steroid treatment as a potential adverse effect 
in other coronaviruses.12
The primary objective of the trial is to concurrently 
evaluate:
 ► Whether treatment of children hospitalised for CAP 
with oral betamethasone is superior to placebo in 
terms of the proportion of children reaching clin-
ical stability (defined as ready for discharge or with 
normal vital signs) at 48 hours after hospitalisation.
 ► Whether inpatient treatment of childhood CAP with 
oral betamethasone is non- inferior to placebo in terms 
of the proportion of children with CAP- related read-
mission to hospital up to 28 days after randomisation.
Secondary objectives include the evaluation of effects 
of oral betamethasone treatment (vs placebo) in chil-
dren hospitalised for CAP on:
 ► Duration of primary hospital stay.
 ► Severity and duration of CAP symptoms.
 ► Parental absence from work and/or child absence 
from routine out- of- home care or school.
 ► Overall duration of antibiotic exposure and inpatient 
days during the follow- up period.
 ► Intensive care unit admissions.
 ► Mortality.
 ► Rate and severity of solicited clinical adverse events.
METHODS AND ANALYSIS
KIDS- STEP is a phase III strategic investigator- initiated, 
randomised, placebo- controlled, fully blinded, multi-
centre superiority trial with two parallel groups. Eligible 
children aged 6 months to less than 14 years and hospi-
talised with CAP at participating sites are randomised 1:1 
to receive either adjunct oral betamethasone 0.1–0.2 mg/
kg per day for 2 days (Celestamine, a liquid formulation; 
0.5 mg/mL betamethasone) or to receive oral placebo 
(matched in aspect, taste and dose) for 2 days in addi-
tion to regular standard of care. Dosing is done by 5 kg 
weight bands (table 1). Randomisation is stratified by site. 
Data on on- going symptoms and healthcare services util-
isation are collected daily until discharge from hospital 
and during three telephonic follow- up visits up to and 
including at 4 weeks. While in hospital, vital signs and 










0 ≥5–<7 1.0 2
1 ≥7–<10 1.5 3
2 ≥10–<15 2.0 4
3 ≥15–<20 2.5 5
4 ≥20–<25 3.0 6
5 ≥25–<30 3.5 7
6 ≥30–<35 4.0 8
7 ≥35–<40 4.5 9
8 ≥40–<45 5.0 10
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temperature are assessed at least every 8 hours. A trial 
flow chart is presented in figure 1.
Trial setting
KIDS- STEP recruits participants in paediatric emergency 
departments of secondary and tertiary hospitals across 
Switzerland where potentially eligible patients present 
and can be admitted for inpatient care. Participants are 
recruited throughout the year.
Trial population
Children from age 6 months weighing at least 5 kg and up 
to a body weight of 45 kg admitted to one of the partici-
pating sites with signs and symptoms of CAP are consid-
ered potentially eligible for participation. Eligibility 
criteria are listed in table 2.
Screening, recruitment and consent
Information material for KIDS- STEP for participating 
sites includes posters placed in the waiting areas of the 
emergency department and a short informational film. A 
KIDS- STEP website will further be created with public and 
member- only areas. Any information material reviewed 
and endorsed by the relevant ethics committee will be 
deposited in the publicly accessible area of the KIDS- 
STEP website.
Eligible children are identified in the emergency 
department when the decision to admit for CAP has 
been made by the treating physician. A screening log 
is kept at each site to document all children admitted 
for CAP. All children are assessed against the inclusion 
and exclusion criteria as listed above, and are consid-
ered eligible for enrolment in this trial if they fulfil all 
the inclusion criteria and none of the exclusion criteria. 
There are no exceptions to eligibility requirements at 
the time of randomisation. Eligibility is reviewed and 
documented by an appropriately qualified member of 
the investigator’s study team (a clinician or nurse who 
has been trained in study procedures and has been dele-
gated the responsibility by the site principal investigator) 
at each participating site before children are randomised 
into the study.
Written informed consent for the child to enter into 
the trial and be randomised must be obtained from the 
parent or guardian and where appropriate the partic-
ipant after explanation of the aims, methods, benefits 
and potential hazards of the trial and before any trial- 
specific procedures are performed. Consent may only 
be obtained once eligibility has been confirmed. The 
English- language version of the participant information 
and informed consent form is available as an online 
supplement to this article. A trial register is kept at each 
Figure 1 Trial flowchart. CAP, community- acquired pneumonia.
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site listing the trial ID numbers to be used. The date of 
randomisation is added to the register.
Randomisation and blinding
Treatment assignment is sequential, through the dispen-
sation of trial medication. Centre- specific randomisation 
lists were prepared in advance following a big stick design 
with a maximum tolerated imbalance of three patients.13 
Randomisation lists were constructed by an independent 
statistician at the Clinical Trial Unit of the University 
Hospital Basel and conveyed to the Pharmaceutical Unit 
at the University Hospital Basel, which prepared the trial 
medication. Randomisation lists are kept concealed at 
the trial pharmacy. Each bottle has a unique code and 
this is entered into the trial database under the partici-
pant’s trial ID.
Blinding is ensured through the use of placebo, which 
is indistinguishable from the active treatment in any way 
but the active ingredient. All caregivers (including nurses 
and treating physicians), the patients and their parents, 
the investigators, the outcome assessors and the data 
analysts are blinded to the allocated treatment.
We envisage optimal blinding because the active drug 
is a product not widely used in Switzerland with very little 
advance knowledge of the aspect, taste and texture of 
the product and individual patients are receiving either 
active treatment or placebo with no cross- over.
Outcome measures and assessments
The co- primary outcomes are:
 ► The proportion of children clinically stable at 48 
hours after randomisation in the active treated group 
Table 2 Eligibility criteria
Inclusion criteria (all must be fulfilled)
At least 6 months of age and less than 14 years 
of age
A.Temperature ≥38°C measured by any method or history of fever in last 48 
hours reported by parents
and
B.at least two of the following signs and/or symptoms:
 ► The presence of cough (observed or reported in last 72–96 hours)
 ► Increased age- specific respiratory rate as defined by American Heart 
Association’s accredited Pediatric Advance Life Support guidelines 
during assessment in the paediatric emergency department (first or 
second triage or clinical examination)
 ► Hypoxaemia (<92% arterial oxygen saturation) in room air as measured 
by pulse oximetry (SpO2)
36 37
 ► Signs of laboured/difficult breathing, including nasal flaring, chest 
retractions, grunting, abdominal breathing and shortness of breath
 ► Clinical signs of lobar pneumonia, including focal dullness to percussion, 
focal reduced breath sounds and crackles with asymmetry
Body weight between 5 kg and 45 kg
Admission to hospital (ie, assignment of an 
inpatient case number or receipt of in- hospital 
treatment in a designated short stay unit)
Clinical diagnosis of CAP (A. and B., right 
column)
Parent and/or child (as age appropriate) willing 
to accept all possible randomised allocations 
and to be contacted for three telephonic follow- 
up visits up to and including at 4 weeks after 
randomisation
Informed consent form for trial participation 
signed by participants and/or caregivers
Exclusion criteria (excluded if any of the following are present)
 ► The presence of local complications (empyema or pleural effusion with clinically identified need for drainage, pneumothorax 
and pulmonary abscess)
 ► Chronic underlying disease associated with an increased risk of very severe CAP or CAP of unusual aetiology, such as 
sickle cell disease, primary or secondary immunodeficiency, chronic lung disease and cystic fibrosis
 ► Bilateral wheezing without focal chest signs and clinical indication for primary administration of steroids (most likely to 
represent respiratory tract infection affecting the medium airways, ie, not pneumonia)
 ► Admission to hospital with a primary clinical diagnosis of bronchiolitis
 ► Inability to tolerate oral medication
 ► Documented allergy or any other known contraindication to any trial medication
 ► Subacute or chronic conditions requiring higher betamethasone equivalent or known primary or secondary adrenal 
insufficiency
 ► Known diabetes mellitus (type 1)
 ► Hospitalisation within the last 2 weeks preceding current admission with the possibility that pneumonia could be hospital- 
acquired or healthcare- associated
 ► Completion of a course of systemic corticosteroids within 2 weeks from enrolment for courses of >5 days
 ► Transfer for any reason to a non- participating hospital directly from the paediatric emergency department
 ► Parents are unlikely to be able to reliably participate in telephone follow- up because of significant language barriers
 ► Participation in another study with an investigational drug within the 30 days preceding and during the present study
 ► Previous enrolment into the current study
 ► Enrolment of the investigator, his/her family members and other dependent persons
CAP, community- acquired pneumonia.
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(oral betamethasone for 2 days) as compared with the 
control group (placebo) (efficacy).
 ► The proportion of children with CAP- related readmis-
sion within 28 days after randomisation comparing 
oral betamethasone and placebo (safety).
Clinical stability is defined as the clinician assessing 
the child as being ready for hospital discharge and/or 
recorded normal respiratory rate, heart rate and oxygen 
saturation. Children discharged before 48 hours after 
randomisation are assumed to be clinically stable at 48 
hours as per last clinician assessment. For respiratory 
rate and heart rate, at least two consecutive age- related 
normal values as specified in the American Heart Associ-
ation’s accredited Pediatric Advance Life Support docu-
mentation is taken to indicate stability. Arterial oxygen 
saturation in room air of 92% or above measured by pulse 
oximetry is considered normal.
CAP- related readmissions are recorded by active surveil-
lance at participating centres and in addition identified 
through parental reporting.
Additional outcomes (box 1) are captured to further 
evaluate the efficacy and safety of adjunct oral steroids in 
the management of childhood CAP.
Trial visit and contact schedules are prepared for each 
child at randomisation and children are followed on that 
same schedule until the final follow- up visit regardless of 
adherence to trial medication. The schedule defines visit 
times (with windows) necessary for data collection. An 
overview of trial contacts is given in figure 2.
Sample size and power
A simulation approach was used to estimate the sample 
size required. Each sample size ni=1, …, 43=580, …, 748 
was evaluated by simulating 9999 times ni individual 
patients. Events were simulated once for the proportion 
of 48 hours clinically stable patients and once for the 
rate of CAP- related readmission, from binomial distribu-
tions assuming the two event types are correlated with a 
correlation coefficient ρ. For each simulation run, each 
co- primary objective was tested with a two- sided type- I 
error level of α=0.05. Since the trial’s success is defined as 
showing a successful result in both co- primary endpoints, 
no correction for multiplicity is required.
To test the superiority of the active treatment arm 
over the placebo arm with regards to the proportion of 
patients achieving clinical stability within 48 hours, Pear-
son’s χ2 test with Yates continuity correction was applied 
in each simulation run. To examine the influence of the 
actual difference in rates on sample size, simulations were 
performed with effect sizes (absolute difference πstability–A–
πstability–P) ranging from 5% to 15%.
To test the non- inferiority of the active versus the 
placebo with regards to hospital readmission rates, we 
constructed in each simulation run the 1–α % CIs for the 
difference in rates, using a continuity- corrected modi-
fication of Wilson score method.14 Non- inferiority was 
determined if the upper bound of the CI lay below the 
specified non- inferiority margin δ=7%. The chosen non- 
inferiority margin was based on clinical relevance and 
decided by the investigators.
Assuming an absolute difference of 10% between 
study arms in terms of the first co- primary endpoint, it 
was assumed that 80% and 70% of children will achieve 
clinical stability within 48 hours in the active and placebo 
arms, respectively. In addition, it was assumed that CAP- 
related rehospitalisation within 28 days is 5% for both 
study arms. Finally, it was assumed that the correlation 
between both endpoints is 0.8, which simulations showed 
to be the most conservative assessment, leading to the 
highest sample size (figure 3).
Under these assumptions, 700 patients need to be 
recruited to the study—for both arms combined—to 
ensure 664 patients for the non- inferiority test, while 
allowing 5% of drop- out.
The incidence rates of the co- primary endpoints are 
difficult to estimate in advance. A substantial deviation 
from the assumed rates may lead to an inappropriate 
sample size due to the critical dependency of the sample 
size estimation on the assumed rates. To counter this 
problem, a sample size re- estimation15 will be performed 
in a blinded manner once a substantial proportion of the 
patients have been recruited and information on both 
co- primary endpoints has been collected. The blinded 
sample size re- estimation (often referred to as an internal 
pilot design) allows adjusting the sample size in case the 
actual rate of events differs substantially from the assump-
tions taken.
For the sample size re- estimation, the overall (ie, not 
treatment arm specific) rates of achieving clinical stability 
and of readmission will be estimated in a treatment- 
blind fashion. The sample size estimation procedure, 
as described above, will be repeated with the updated 
assumptions. If, based on the newly collected data, a larger 
sample size is required for the study, the overall sample 
size will be increased to the new number, preserving 
Box 1 Secondary outcomes
 ► Time to hospital discharge after index hospitalisation in days.
 ► Time away from routine childcare and/or pre- school/school (for par-
ticipating children) and away from work (for parents) in days up to 
28 days after randomisation.
 ► Total antibiotic exposure in days up to 28 days after randomisation.
 ► Total duration of hospitalisation in days up to 28 days after 
randomisation.
 ► Proportion of children (re)treated with antibiotics after discharge for 
any reason at 28 days after randomisation.
 ► Proportion of children admitted to intensive care during the initial 
hospitalisation and up to 28 days after randomisation.
 ► Proportion of children experiencing solicited side effects of the trial 
treatment and/or serious adverse events.
 ► Duration of individual moderate–severe CAP symptoms in days 
assessed by a telephone questionnaire at week 1, 2 and 4 after 
randomisation.
 ► Mortality up to 28 days after randomisation.
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Figure 2 Trial schedule: X* indicates to be collected, if child is still in hospital and until discharge home. X§ indicates to be 
collected before discharge home. (X) indicates tests that may be done if the child’s condition requires it or allows it but are not 
mandatory. X° indicates tests to be done if visit is face to face.
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the study’s power. If the newly calculated sample size is 
smaller or equal to the originally calculated sample size, 
no changes will be made in the study’s sample size.
The sample size re- estimation will be performed after 
80% of the patients have been recruited and data on both 
co- primary endpoints collected, or after a seasonality 
peak in recruitment is finished (ie, spring) and at least 
65% of patients have been recruited. Recruitment may be 
extended if the sample size re- estimation suggests that an 
increased sample is necessary.
Analysis plan
The analysis will be performed by the trial statistician 
using the R language and environment for statistical 
computing (V.3.6 or higher). Reporting will follow the 
Consolidated Standards of Reporting Trials guidelines.
The All Randomised Set (ARS) will consist of all 
patients randomised to the study; protocol violations will 
be disregarded in this data set.
The complete follow- up (CFUP) set will consist of all 
patients randomised to the study who were not lost to 
follow- up after 28 days; patients with major protocol viola-
tions will be excluded from this set.
The study has two co- primary endpoints, each analysed 
separately:
Stability rate: the proportion of children achieving clin-
ical stability within 48 hours post randomisation.
Readmission rate: the proportion of children read-
mitted to hospital within 28 days post randomisation.
The treatment is declared successful on showing success 
for both endpoints together. Each endpoint will be anal-
ysed and tested separately using a type- I error rate level 
of α=0.05.
Rates of achieving clinical stability will be calculated 
for each study arm, and the risk difference between them 
reported with 95% CI. A logistic regression model will be 
fit with study arm as fixed predictor to compare the odds 
of achieving clinical stability between the study arms. 
An OR, risk differences and respective 95% CIs will be 
presented. The superiority analysis will be performed on 
the ARS and based on the intention to treat principle.
To test the non- inferiority of the active treatment 
compared with placebo treatment with regards to read-
mission rates, the 95% CI of the difference between the 
two rates (preadmission−A−preadmission−P) will be calculated and 
compared with the predefined non- inferiority margin 
(δ=7%). Non- inferiority of the treatment will be declared 
if the upper bound of the 95% CI is smaller than the non- 
inferiority margin. The non- inferiority analysis will be 
performed on the CFUP set based on the principle that 
this is the more conservative approach in a non- inferiority 
analysis.
If substantial deviations of the analysis as outlined 
in these sections are needed for whatever reason, the 
protocol will be amended. All deviations of the analysis 
from the protocol or from the detailed analysis plan will 
be listed and justified in a separate section of the final 
statistical report.
Careful trial planning and conduct minimise the occur-
rence of missing data as far as possible.
For the ARS, missing values will be replaced by multiple 
imputation using chained equations based on predefined 
baseline characteristics.
The analyses described above of ARS data will be 
performed on each imputed data set, and results 
combined using Rubin’s rule for multiple imputation.
As a sensitivity analysis, the primary analysis will be 
repeated for each of the co- primary endpoints using the 
alternative analysis set: for superiority using the CFUP set 
and for non- inferiority using the ARS.
A detailed analysis plan for all secondary objectives will 
be finalised before the trial’s database closure and will be 
under version control at the Clinical Trial Unit, Univer-
sity of Basel.
Ancillary and substudies
Substudies will have their own analysis plans, which will 
be finalised before the respective databases are locked.
Ancillary study: impact on nasopharyngeal microbiology: 
Given the expected immunomodulatory effects of 
adjunct corticosteroids, different patterns of change 
in viruses and bacteria in the airways may be observed 
in children exposed to betamethasone and placebo. 
This ancillary study will, therefore, evaluate changes 
in the presence and load of viruses and bacteria in the 
nasopharynx during adjunct corticosteroid treatment, 
comparing baseline and pre- discharge nasopharyngeal 
samples.
Figure 3 Required sample size simulations for different 
strengths of correlation between the primary endpoints.
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Substudy 1: exhaled air pneumonia diagnostics: 
Definitive identification of a causative agent in child-
hood CAP is hindered by the fact that significant samples 
cannot generally be obtained from the lower airways and 
the relevance of pathogens detected in upper airways 
secretions is not always clear. This substudy will, therefore, 
evaluate a novel non- invasive diagnostic method (mass 
spectrometry of exhaled air) to determine the relation-
ship between pathogen identification in nasopharyngeal 
samples by PCR and mass spectrometry of exhaled air.
Substudy 2: antibody-secreting cell (ASC) response to infection: 
Determining the causative pathogen of childhood CAP 
is complicated by the low yield of blood cultures and 
difficulty obtaining specimens from the lower respiratory 
tract of children.16 Therefore, clinicians attempt to detect 
potential pathogens in upper respiratory tract (URT) 
specimens. However, PCR of URT samples and immuno-
globulin M (IgM) serology are unreliable in differenti-
ating infected patients and carriers suffering from CAP 
caused by several pathogens.16 17 We recently demon-
strated that the detection of pathogen- specific IgM ASCs 
using the enzyme- linked immunospot assay differenti-
ated between M. pneumoniae infection and carriage.18 M. 
pneumoniae- specific IgM ASCs were detected only for a few 
days or weeks after symptom onset, while M. pneumoniae’s 
DNA in the URT and/or specific IgM in serum persisted 
for months.19 Therefore, pathogen- specific ASCs may be 
an optimal target for determining disease aetiology in 
childhood CAP. The objective of this substudy is to eval-
uate the presence and kinetics of pathogen- specific ASCs 
against several CAP pathogens in patients of the KIDS- 
STEP study, and to compare ASCs to DNA/RNA load in 
URT and serum antibody levels.
Substudy 3: duration of viral shedding in children tested positive 
for SARS-CoV-2
Evidence from observational studies in adults showed a 
longer duration of virus shedding in lower airways after 
prolonged treatment with steroids during infections with 
related SARS- CoV-1 or MiddleEast respiratory syndrome- 
related coronavirus.20 21 Lower airway shedding has low 
impact on transmission but extended upper airway shed-
ding would be an important finding for infection control 
strategies. In children tested positive for SARS- CoV-2 in 
the URT at admission or during the initial hospitalisation, 
the proportion of children with persistent detection of 
SARS- CoV-2 at 1 week and 2 weeks after randomisation 
will be assessed.
Substudy 4: acceptability of and information recall after video-
supported informed consent
Audiovisual aids for informing patients, parents and 
the general public are increasingly used in clinical 
research.22 23 Although they are widely accepted to be 
beneficial, little evidence exists on their effectiveness 
and the way they work. The substudy aims at comparing 
parental information recall on the key study aspects and 
assessing the acceptability of the informational video. A 
standardised questionnaire with six knowledge and three 
perception items is added to the telephone follow- up at 1 
week for all parents.
 
Substudy 5: impact of corticosteroids on the pulmonary 
microbiome diversity
Although the human microbiome exhibits high inter- 
individual variation and it's influence on human health 
and disease has been increasingly well established in 
recent years, the impact of pulmonary microbiome diver-
sity (MD) on the severity and course of CAP in humans 
is unknown. Furthermore, the extent to which systemic 
corticosteroids affect the lung microbiome remains 
unclear. The KIDS- STEP- MD substudy examines the 
effects of systemic corticosteroid and antibiotic treatment 
on the respiratory microbiome as assessed in a subset of 
patients. Nasopharyngeal and rectal swabs and urinary 
samples are collected until day 28 in order to characterise 
changes of the human microbiome both on a taxonomic 
and a functional level.
Monitoring
Representatives of the trial management team and a 
designated external study monitor from the Clinical Trial 
Unit, University of Basel, conducted a site initiation visit 
at each study site to inspect the site facilities, verify qual-
ifications of the local investigators and inform the local 
teams of responsibilities and the procedures for ensuring 
adequate and correct documentation and use of the elec-
tronic data capture system as well as providing training on 
implementing all trial activities.
In addition, the study monitor will conduct three 
routine monitoring visits per site, the first after inclu-
sion of 5–10 participants, the second after inclusion of 
40–50 participants and the third after inclusion of the 
last participant, as well as a site closure visit together with 
representatives of the trial management team at the end 
of the study to resolve any remaining queries.
The local investigators ensure that source data and 
documents are made accessible to the study monitor and 
answer questions posed by the study monitor.
An independent data monitoring committee (IDMC) 
composed of external experts monitors the accrued data 
for arising evidence for treatment harm. Additional roles 
for the IDMC include consideration of implications of 
arising external evidence for safety and trial continuation, 
as well as advising on protocol modifications proposed by 
the investigators.
In accordance with International Council for Harmoni-
sation of Technical Requirements for Pharmaceuticals for 
Human Use (ICH) Good Clinical Practice (GCP) guide-
lines,24 audits may be performed by the ethics committee 
and competent authority during the course of the study.
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ETHICS AND DISSEMINATION
Ethical and regulatory compliance
Prior to study conduct, protocol, proposed patient infor-
mation, consent form and other study- specific documents 
were approved by the local ethics committee of the trial 
centre (Ethikkommission Nordwest und Zentralschweiz, 
study no. 2018–00563), other local ethics committees in 
Switzerland for participating sites and Swissmedic (2018 
DR 3070).
The study category under Swiss law is class C, that is, 
the drug under investigation is not licensed in Switzer-
land. However, celestamine is licensed for medical use 
in Germany, including recommendations for use in 
children.
This study is registered on https:// clinicaltrials. gov 
(NCT03474991) and on the Swiss National Clinical Trials 
Portal (SNCTP000002864).
The study is carried out according to the protocol and 
with principles enunciated in the current version of the 
Declaration of Helsinki,25 the guidelines of GCP issued 
by ICH,24 the European Directive on medical devices 
93/42/EEC and the ISO Norm 14155,26 and ISO 14971, 
the Swiss Law and Swiss regulatory authority’s require-
ments. The lead ethics committee and regulatory author-
ities receive annual safety and interim reports and will be 
informed about study stop/end in agreement with local 
requirements.
Patient and public involvement
This protocol was written without patient involvement. 
Patients or guardians were not invited to comment on the 
study design or to contribute to the writing or editing of 
this document for readability or accuracy.
Dissemination of results
The data from all centres will be analysed together and 
published as soon as possible in peer- reviewed journals, 
as well as being presented at national and international 
conferences.
The results of this trial will be submitted for Open Access 
publication in high- impact peer- review journals likely to 
be read by health professionals in the management of 
CAP in children in Europe. The work will be presented 
at key medical conferences. To maximise the impact of 
the trial across Europe, its findings will be disseminated 
more widely through abstracts for oral and poster presen-
tations submitted to some of the main relevant national 
and international conferences.
A study website will be developed providing informa-
tion for collaborators, participants and the public, with 
the results of the trial eventually posted here. The social 
media presence of the organisations involved will also be 
used to highlight news about the trial.
For the main results of the trial, a press release will be 
produced, in collaboration with the press office of the 
journal publishing the results, which will be distributed to 
Swiss and European media, to encourage press coverage. 
This will enable a wider audience to be reached.
TRIAL STATUS AND DISCUSSION
The first participant was enrolled in October 2018. 
Currently, 141 children have been enrolled in the 
trial. Follow- up has been completed for 138, with the 
remaining 3 still being within the 4- week follow- up 
interval. Recruitment accrual is at 36% of target, mainly 
due to (1) late/stepwise opening of several study sites, 
(2) slow performance in the first winter season and (3) 
complete absence of recruitment during the COVID-19 
lockdown in Switzerland (March–April 2020). Between 
December 2019 and March 2020, actual recruitment has 
exceeded pre- trial projections. Recruitment is projected 
to be complete in late 2021. There has not been any loss 
to follow- up. Until publication, no emergency unblinding 
of any participants occurred.
Only few small trials have addressed the potential impact 
of oral steroid treatment in CAP during childhood.5 Nagy 
et al reported a significant reduction in fever duration (2 
days vs 4 days) and length of stay (11 days vs 16.5 days) in 
children with severe CAP receiving methylprednisolone 
for 5 days compared with children receiving placebo in a 
randomised trial with 59 participants.27 A randomised trial 
comparing adjunct dexamethasone or methylprednisolone 
against standard of care (no placebo) planning to enrol 40 
participants was being set up but has been withdrawn prior 
to recruitment.28 A placebo- controlled randomised trial 
of adjunct corticosteroids in CAP complicated by pleural 
effusion and/or empyema with 56 participants has been 
completed,28 but has not yet reported on its findings. An 
observational analysis using propensity scores found that 
adjunct corticosteroids were associated with a shorter 
hospital stay only in children also receiving beta- agonist 
therapy, concluding that any benefit might only be seen in 
children with acute wheezing.29 At the same time, children 
without beta- agonist therapy experienced longer hospital 
stays and increased rates of readmission when treated 
with steroids in this study. However, one- third of children 
with steroid treatment received long- term medication for 
asthma, and both intensive care unit admission and invasive 
ventilation were significantly more frequent in the steroid 
group. The stratified analysis comparing steroid effects 
between beta- agonist co- treatment positive and negative 
children was unadjusted for these factors, leading to the 
conclusion that the steroid group may have consisted of 
subgroups of (a) asthmatic children, that would respond 
well to steroids, and (b) non- asthmatic children that were 
more severely ill than children not treated with steroids and 
that would be less likely to be co- treated with beta- agonists. 
Thus, the different effect of steroids in children with or 
without treatment with beta- agonists may simply reflect very 
different patient groups with different decision criteria for 
steroid treatment. A subgroup analysis in another retrospec-
tive study with 2000 children with CAP found that the risk 
for treatment failure, defined as switch to another antibi-
otic therapy regimen than initially prescribed, was higher in 
non- asthmatic children with CAP when treated with adjunct 
steroids.30 However, in this subgroup, only 5% of children 
received steroids and again residual confounding is likely to 
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limit the conclusions that can be drawn. All in all, there is 
a lack of randomised controlled trials with sufficient power 
and high external validity to provide a definitive answer to 
the question of the effect of adjunct steroids in children 
hospitalised with CAP. Betamethasone was selected as the 
investigational drug because it is the steroid most widely 
used in respiratory conditions in the trial setting. A 2016 
Cochrane review on steroids in asthma identified only one 
comparative trial on the use of different steroids in chil-
dren.31 There was no difference in effect of relative strength 
adjusted doses of dexamethasone and prednisolone. Beta-
methasone and dexamethasone have comparably high 
glucocorticoid activity. We, therefore, expect the findings 
to be transferable to the use of lower potency steroids.
In contrast to previous trials, we chose clinical stability at 
48 hours as the endpoint for superiority. Clinical stability 
is relevant to patients and their families as a prerequisite 
for hospital discharge and can have considerable socio-
economic impacts on the child and parents by allowing 
a return to normal activity for the whole family. A rapid 
recovery with no respiratory problems and no need for 
supplemental oxygen represents directly patient- relevant 
components of this outcome.
The average length of stay of hospitalised children with 
CAP is 2 days and by 3–4 days more than 75% of chil-
dren with this diagnosis have been discharged home.32 33 
This reflects the relatively rapid recovery of children with 
CAP compared with adults. An early assessment of clinical 
stability at 48 hours has, therefore, been selected to be of 
main interest.
Following WHO’s recommendation to not routinely 
administer steroids in patients with suspected or 
confirmed COVID-19, we were initially facing concerns 
on whether to keep the trial open during the pandemic. 
Russell et al reviewed the evidence on use of steroids in 
relation to COVID-19 and concluded that the evidence 
at the beginning of the pandemic did not support steroid 
administration.12 The only paediatric evidence included 
in this review was a study on RSV and corticosteroids and 
it showed neither a beneficial nor a detrimental effect.34
The Randomised Evaluation of COVID-19 Therapy 
(RECOVERY) trial provided evidence for a benefit of 
steroids in hospitalised COVID-19 patients.35 Although 
this trial did not exclude children, the average age of 
participants was around 65 years and only few paediatric 
patients were included. While this evidence is not yet 
sufficiently conclusive to support routine administration 
of corticosteroids to paediatric COVID-19 patients, it is 
clear that their use may be an important adjunct therapy 
for the disease.
Paediatric CAP is a common condition with diverse aeti-
ology. Although lethality in high- resource settings is low, 
an adjunct therapy reducing length of hospital stay and 
shortening the duration of symptoms has a high poten-
tial to reduce strain on healthcare resources and improve 
children’s and parents’ well- being. The KIDS- STEP trial 
will provide conclusive evidence on the effectiveness and 
safety of steroids for this purpose.
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